The announcement coincides with the USCAP 112th Annual Meeting held March 11-16 at the New Orleans Ernest N. Morial Convention Center in New Orleans, Louisiana. "We are delighted to further extend our partnership in this emerging era of personalized medicine." The increasing prevalence of chronic conditions is predicted to intensify the urgency of pathologists seeking to adopt innovative digital pathology solutions to improve existing patient diagnostic imaging methods and reduce the high cost associated with traditional diagnostics. Technological advances in the past decade and the numerous benefits of digital pathology are driving the practice to become widely adopted. Agilent and Visiopharm have collaborated since 2020, developing an integrated solution comprising Visiopharm's portfolio of leading artificial intelligence (AI)-driven precision pathology software and Agilent's automated pathology staining solutions.

The round includes participation from Highline Capital Management, Triangle Peak Partners, and Alpha Intelligence Capital as well as existing investors including Scale Venture Partners, Hitachi Ventures, ROBO Global, Emerald Development Managers, and Razor's Edge Ventures. It will use the infusion of capital to scale its commercial operations. This includes expanding its sales, marketing, and support teams as well as growing distribution partnerships following its recent OEM agreement with Siemens Healthineers. Proscia will also increasingly focus on its regulatory strategy on the heels of its CE IVDR certification. Founded in 2014 by a team of clinicians at Johns Hopkins and the University of Pittsburgh, Proscia is a software company that is changing the way the world practices pathology to transform cancer research and diagnosis. With its Concentriq software platform, Proscia is accelerating the transformation to digital pathology, which centers around high-resolution images of tissue biopsies, as the new standard of care.

Joint Pathology Center (JPC), the premiere pathology reference center for the U.S. government, has selected Proscia's Concentriq platform for a complete transformation of its pathology practice. Proscia is a Philadelphia, PA-based provider of digital and computational pathology solutions. The Joint Pathology Center seeks to preserve, modernize, and grow the nation's oldest tissue repository to promote biomedical research. Over the past century, it has collected approximately 55 million glass slides, 31 million paraffin-embedded tissue blocks, and over 500,000 wet tissue samples, which have provided critical insight into our understanding of current and future disease; data from the repository was used to sequence the 1918 influenza virus that killed more than 40 million people worldwide and can similarly help us to combat COVID-19. The rise of digital pathology, which captures high-resolution images of tissue specimen, is enabling JPC to realize even more value from its data by making it readily accessible to clinicians, pathologists, and healthcare data analysts.

Digital pathology specialist Proscia has been working hard to change the current pathology narrative. The Philadelphia, PA-based company has made several moves to accomplish this goal and its most recent move is a collaboration with the University of California, San Francisco (UCSF). Proscia builds software and has a platform for imaging workflow management that allows a pathologist in the lab to take digitized images of the glass slides the tissue biopsy sites on and move these images through workflows. The company uses its computational AI-based applications to find patterns in the imaging and transform that information into something meaningful for the pathologist. However, Proscia doesn't have a laboratory and that's where UCSF comes in, said Nathan Buchbinder, the firm's co-founder and Chief Product Officer.

The U.S. is facing a doctor shortage that is getting worse as an aging population of Baby Boomers lives longer, increasing the demand for medical professionals. But doctors are not the only ones feeling the pinch. Pathologists, scientists who study disease, have also been hit hard, with an overall decline in professionals from 2007 to 2017. "With many senior pathologists expected to retire in the coming years, a'pathologist gap' is likely to increase through 2030," according to a 2018 study by the National Center for Biotechnology Information. David West, co-founder and CEO of digital startup Proscia, said his company is hoping to help pathologists use their time more efficiently.

If you became concerned about a mole on your back -- perhaps it had become painful or looked unsightly -- your doctor might decide to remove it and have it evaluated. She'd send it to a pathology lab, where a sample of the tissue would be prepared in the form of a slide. It would then be sent to a pathologist, who would examine the slide to determine whether the tissue had any problematic elements, like cancer. After taking a look, the pathologist might ship it to a specialist at another lab for a second opinion. Each time the slide is moved, it is packed up and shipped to a different address.

Entopsis: Entopsis is a Miami based startup building a device NuTec (Nanoscale Unbiased Textured Capture) utilizing artificial intelligence. NuTec is mainly focussed on cancer, autoimmune diseases. SkinVision: SkinVision is a skin cancer awareness and tracking app that allows you to understand your risk factors for skin cancer and keep track of your moles. CureMetrix: CureMetrix is developing a next-generation based medical image analysis tool for mammography. OncoraMedical: Oncora Medical is focussed on using machine learning and big data in radiation oncology. This clinical decision support software will provide aid to oncologists based on the results of sophisticated data analytics.

It is a centuries-old image of good science: the lab-coated expert, hunched over a microscope analyzing a glass slide. Proscia wants to resign it to history – at least, when it comes to battling cancer. The Baltimore-based startup, founded out of Johns Hopkins University in 2014, wants to bring artificial intelligence to dermatopathology, the study of skin-born diseases. It has developed an AI module that can greatly enhance the accuracy and scope of tissue analysis. That means better results, and lower costs.